Baillie Gifford & Co
TSVT

Baillie Gifford & Co’s 2seventy bio TSVT Stock Holding History

Baillie Gifford & Co’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-286
Closed -$2.92K – 425
2023
Q1 		$2.92K Hold
286
– – ﹤0.01% 433
2022
Q4 		$2.68K Hold
286
– – ﹤0.01% 466
2022
Q3 		$4K Hold
286
– – ﹤0.01% 457
2022
Q2 		$4K Hold
286
– – ﹤0.01% 461
2022
Q1 		$5K Hold
286
– – ﹤0.01% 469
2021
Q4 		$7K Buy
+286
New +$8.92K ﹤0.01% 469

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Baillie Gifford & Co's TSVT Position: Q2 2023 in Review

Baillie Gifford & Co sold out of 2seventy bio (TSVT) in Q2 2023, closing a stake of 286 shares — an estimated $2.92K sold.

Baillie Gifford & Co first reported a position in TSVT in Q4 2021 and held it in 6 quarters. The position peaked at $7K in Q4 2021. 149 funds tracked by Wall St. Rank hold TSVT as of Q2 2023.

  • Baillie Gifford & Co reported no remaining 2seventy bio position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 286 2seventy bio shares in Q2 2023, an estimated $2.92K.
  • Baillie Gifford & Co first reported a position in 2seventy bio in Q4 2021 and held it in 6 quarters.
  • Baillie Gifford & Co's 2seventy bio position peaked at $7K in Q4 2021.
  • 149 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.